Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 75


Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies.

Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schröder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P.

Ann Intern Med. 2008 Oct 7;149(7):461-71, W83-8.


IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans.

Hernandez W, Grenade C, Santos ER, Bonilla C, Ahaghotu C, Kittles RA.

Carcinogenesis. 2007 Oct;28(10):2154-9. Epub 2007 Aug 27.


IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Chia D, Crawford ED, Kaaks R, Hayes RB.

Int J Cancer. 2007 Nov 15;121(10):2267-73.


Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.

Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S, Egevad L, Rohrmann S, Linseisen J, Pischon T, Boeing H, Johnsen NF, Tjønneland A, Grønbaek H, Overvad K, Kiemeney L, Bueno-de-Mesquita HB, Bingham S, Khaw KT, Tumino R, Berrino F, Mattiello A, Sacerdote C, Palli D, Quirós JR, Ardanaz E, Navarro C, Larrañaga N, Gonzalez C, Sanchez MJ, Trichopoulou A, Travezea C, Trichopoulos D, Jenab M, Ferrari P, Riboli E, Kaaks R.

Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1121-7.


Serum levels of insulin-like growth factor-I and insulin-like growth factor-I binding protein-3: quality control for studies of stored serum.

Berrigan D, Potischman N, Dodd KW, Nicar M, McQuillan G, Lavigne JA, Barrett JC, Ballard-Barbash R.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):1017-22.


The role of insulin-like growth factor binding proteins.

Holly J, Perks C.

Neuroendocrinology. 2006;83(3-4):154-60. Epub 2006 Oct 13. Review.


Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.

Severi G, Morris HA, MacInnis RJ, English DR, Tilley WD, Hopper JL, Boyle P, Giles GG.

Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1137-41.


Insulin-Like Growth Factor (IGF) family and prostate cancer.

Gennigens C, Menetrier-Caux C, Droz JP.

Crit Rev Oncol Hematol. 2006 May;58(2):124-45. Epub 2006 Jan 18. Review.


IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.

Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.

Eur Urol. 2006 Feb;49(2):286-92; discussion 292. Epub 2005 Dec 7.


A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial.

Meyer F, Galan P, Douville P, Bairati I, Kegle P, Bertrais S, Czernichow S, Hercberg S.

Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2269-72.


Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy.

Freedland SJ, Sokoll LJ, Platz EA, Mangold LA, Bruzek DJ, Mohr P, Yiu SK, Partin AW.

J Urol. 2005 Oct;174(4 Pt 1):1266-70.


Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.

Marszalek M, Wachter J, Ponholzer A, Leitha T, Rauchenwald M, Madersbacher S.

Eur Urol. 2005 Jul;48(1):34-9. Epub 2005 Apr 2.


Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.

Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E.

Cancer Causes Control. 2005 Apr;16(3):255-62.


Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.

Nam RK, Trachtenberg J, Jewett MA, Toi A, Evans A, Emami M, Narod SA, Pollak M.

Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1270-3.


The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models.

Yakar S, Leroith D, Brodt P.

Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):407-20. Review.


Pitfalls of immunoassay and sample for IGF-I: comparison of different assay methodologies using various fresh and stored serum samples.

Khosravi J, Diamandi A, Bodani U, Khaja N, Krishna RG.

Clin Biochem. 2005 Jul;38(7):659-66.


Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival.

Inman BA, Harel F, Audet JF, Meyer F, Douville P, Fradet Y, Lacombe L.

Eur Urol. 2005 May;47(5):695-702. Epub 2005 Jan 24.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk